Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416027 | 0.90 | DRD3 (0.63) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10078397 | 0.90 | QDPR (0.53) | DRD2HTR2AHTR2CSLC6A2SLC6A4 | |
| SCHEMBL2908786 | 0.83 | DRD3 (0.51) | DRD2DRD3HTR2AHTR2CSLC6A2 | |
| SCHEMBL1823938 | 0.82 | SLC6A2 (0.41) | DRD2DRD3HTR2AHTR2CSLC6A2 | |
| SCHEMBL15829965 | 0.81 | DRD2 (0.60) | DRD2DRD3HTR2AHTR2CSLC6A2 | |
| SCHEMBL21148630 | 0.81 | DRD3 (0.54) | DRD2DRD3HTR1ADRD4DRD1 | |
| SCHEMBL10209560 | 0.80 | SCD5 (0.45) | DRD2DRD3SCD5DRD4 | |
| SCHEMBL13416045 | 0.80 | DRD2 (0.51) | DRD2DRD3HTR2AHTR2CSLC6A2 | |
| SCHEMBL10057694 | 0.80 | DRD3 (0.54) | DRD2DRD3SCD5HTR1AHTR2B | |
| SCHEMBL18742027 | 0.80 | SCD5 (0.46) | DRD2DRD3SCD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| WO-2008101953-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002441-A1 | 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS | AP2A1, P2RX5, AP3M1 | DRD2 1191/4885DRD3 2095/4885SCD5 513/4885 |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | PRSS1, SERPINB1, SPINT2 | DRD2 4641/4885DRD3 4316/4885SCD5 725/4885 |
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | DRD2 415/4885DRD3 301/4885SCD5 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.